International Clinical Trial: An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07124039) titled 'An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population' on Aug. 8.

Study Type: Observational

Primary Sponsor: Bayer

Condition: Chronic Kidney Disease Type 2 Diabetes Mellitus

Intervention: Drug: Finerenone (Kerendia, BAY948862)

Recruitment Status: Not recruiting

Date of First Enrollment: July 16, 2025

Target Sample Size: 5000

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07124039

Published by HT Digital Content...